Karnataka Suspends Pfizer Warehouse Amid Fake Drugs Racket

• Karnataka has cancelled 16 pharmaceutical licenses and suspended eight others, including a Pfizer supply depot, due to a widening counterfeit medicine racket.
• The Pfizer depot suspension was attributed to the company's alleged non-cooperation with the Special Investigation Team (SIT) probing the fake drugs.
• The racket, uncovered by an August 18 FSDA raid, involved refilling low-cost medicines into new vials and relabeling them to imitate expensive, multinational brands, including Pfizer.
• Counterfeit drugs, lacking active ingredients and potentially containing harmful substances, posed serious health risks and were distributed across multiple states and to reputed hospitals.
• A suspected kingpin, Prashanth, is believed to be operating part of the network from Azerbaijan, leading the Karnataka government to seek central assistance for extradition.

The health department has issued a stark warning regarding the severe public health risks posed by these counterfeit drugs.

Authorities in Karnataka have taken decisive action against a sprawling counterfeit medicine racket, leading to the cancellation of 16 pharmaceutical licenses and the suspension of eight others, including a local supply depot operated by global pharmaceutical giant Pfizer. This significant move, announced by Health Minister U T Khader, follows an intensive investigation into a network accused of manufacturing and distributing spurious and potentially life-threatening drugs across Bengaluru and beyond.

The crackdown originated from an August 18 raid conducted by the Food Safety and Drugs Administration (FSDA) on farmhouse premises located in the Bidadi and Dodderi areas of Bengaluru South district. This initial operation uncovered counterfeit medicines with an estimated value of nearly Rs 5 crore, alongside fake billing documents, machinery for filling injections, and fraudulent labels. The sheer scale of this discovery prompted the state government to establish a Special Investigation Team (SIT) to delve deeper into the illicit operation.

The suspension of Pfizer's C&F depot in Kempalinganahalli, Nelamangala taluk, Bengaluru Rural district, stems from allegations of non-cooperation with the ongoing investigation. Minister Khader explicitly stated that Pfizer's sales in the state were halted because the company allegedly failed to assist the SIT. He also noted a broader pattern of unresponsiveness among distributors when asked to recall medicines already in circulation, suggesting a potential proximity to the producers of these illicit products.

FSDA's preliminary findings indicate that the Bidadi farmhouse served as a hub for procuring low-cost medicines from neighboring states. These cheaper drugs were then refilled into new vials and relabeled to mimic expensive, imported life-saving drugs from multinational brands, with Pfizer's branding specifically targeted. The counterfeit labels even featured QR codes designed to appear authentic, though officials discovered these codes were entirely non-functional when scanned, a detail intended to bypass casual scrutiny at the point of sale.

The health department has issued a stark warning regarding the severe public health risks posed by these counterfeit drugs. Investigations reveal that the spurious products lacked active medicinal ingredients and, in some instances, may have contained harmful substances. This poses a grave danger to patients, particularly those undergoing treatment for critical illnesses, who rely on the efficacy and safety of their medications.

The reach of this Bengaluru counterfeit medicine racket extends far beyond Karnataka's borders, impacting several other states including Himachal Pradesh, Telangana, and Tamil Nadu. Alarmingly, the illicit supply chain infiltrated reputed hospitals that unknowingly procured these fake drugs. Investigators have identified 24 linked agencies, with 17 already shut down, and Minister Khader alluded to a suspected 'kingpin' orchestrating the operation. Sources close to the investigation have identified a man named Prashanth, believed to be operating part of the network from Azerbaijan, prompting the Karnataka government to seek assistance from the central government for his extradition due to jurisdictional complexities.

The regulatory response has been swift and comprehensive, with the Karnataka government demonstrating a firm stance against pharmaceutical malpractices. The cancellation of 16 pharma licenses and the suspension of eight others, including the Pfizer India depot suspension, underscore the commitment to safeguarding public health and maintaining the integrity of the drug supply chain. The minister's statements highlight the critical importance of cooperation from pharmaceutical entities during regulatory investigations, as non-compliance can lead to severe penalties.

Among the substantial evidence seized during the FSDA Karnataka fake drug raid were 5,640 vials of a counterfeit injection, falsely branded under a healthcare company's name, with a value exceeding Rs 3.38 crore. This single haul represented a significant portion of the total seizure. Additionally, officials recovered over 1,500 vials of another counterfeit injectable and more than 260 vials of a different spurious drug, further illustrating the scale and sophistication of the counterfeit drug supply chain India is grappling with.

Compliance officers in the pharmaceutical sector, especially those operating in India, must immediately review their supply chain due diligence processes and ensure robust protocols for cooperating with regulatory investigations, as non-compliance can lead to severe penalties like license suspensions. Legal counsel should advise clients on potential product liability risks and the importance of stringent supplier vetting to avoid unknowingly distributing counterfeit products.

Source: Original reporting via Times of India